Literature DB >> 28848013

Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.

Bartolome Moya1, Isabel M Barcelo2, Sachin Bhagwat3, Mahesh Patel3, German Bou4, Krisztina M Papp-Wallace5,6, Robert A Bonomo5,6,7, Antonio Oliver2.   

Abstract

Multidrug-resistant Acinetobacter baumannii has rapidly spread worldwide, resulting in a serious threat to hospitalized patients. Zidebactam and WCK 5153 are novel non-β-lactam bicyclo-acyl hydrazide β-lactam enhancer antibiotics being developed to target multidrug-resistant A. baumannii The objectives of this work were to determine the 50% inhibitory concentrations (IC50s) for penicillin-binding proteins (PBP), the OXA-23 inhibition profiles, and the antimicrobial activities of zidebactam and WCK 5153, alone and in combination with β-lactams, against multidrug-resistant A. baumannii MICs and time-kill kinetics were determined for an A. baumannii clinical strain producing the carbapenemase OXA-23 and belonging to the widespread European clone II of sequence type 2 (ST2). Inhibition of the purified OXA-23 enzyme by zidebactam, WCK 5153, and comparators was assessed. All of the compounds tested displayed apparent Ki values of >100 μM, indicating poor OXA-23 β-lactamase inhibition. The IC50s of zidebactam, WCK 5153, cefepime, ceftazidime, meropenem, and sulbactam (range of concentrations tested, 0.02 to 2 μg/ml) for PBP were also determined. Zidebactam and WCK 5153 demonstrated specific high-affinity binding to PBP2 of A. baumannii (0.01 μg/ml for both of the compounds). The MICs of zidebactam and WCK 5153 were >1,024 μg/ml for wild-type and multidrug-resistant Acinetobacter strains. Importantly, combinations of cefepime with 8 μg/ml of zidebactam or WCK 5153 and sulbactam with 8 μg/ml of zidebactam or WCK 5153 led to 4- and 8-fold reductions of the MICs, respectively, and showed enhanced killing. Notably, several of the combinations resulted in full bacterial eradication at 24 h. We conclude that zidebactam and WCK 5153 are PBP2 inhibitors that show a potent β-lactam enhancer effect against A. baumannii, including a multidrug-resistant OXA-23-producing ST2 international clone.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  MDR A. baumannii; PBP IC50; WCK 5153; zidebactam; β-lactam enhancer

Mesh:

Substances:

Year:  2017        PMID: 28848013      PMCID: PMC5655067          DOI: 10.1128/AAC.01238-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

Review 1.  Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.

Authors:  L Poirel; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2006-09       Impact factor: 8.067

Review 2.  A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections.

Authors:  David J Ritchie; Alexandria Garavaglia-Wilson
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

3.  OmpA is the principal nonspecific slow porin of Acinetobacter baumannii.

Authors:  Etsuko Sugawara; Hiroshi Nikaido
Journal:  J Bacteriol       Date:  2012-05-25       Impact factor: 3.490

4.  In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.

Authors:  Shazad Mushtaq; Marina Warner; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2010-08-26       Impact factor: 5.790

5.  OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.

Authors:  Akihiro Morinaka; Yuko Tsutsumi; Mototsugu Yamada; Kenji Suzuki; Takashi Watanabe; Takao Abe; Takeshi Furuuchi; Seiichi Inamura; Yoshiaki Sakamaki; Nakako Mitsuhashi; Takashi Ida; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2015-06-18       Impact factor: 5.790

6.  Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Authors:  Krisztina M Papp-Wallace; Baui Senkfor; Julian Gatta; Weirui Chai; Magdalena A Taracila; Veerabahu Shanmugasundaram; Seungil Han; Richard P Zaniewski; Brian M Lacey; Andrew P Tomaras; Marion J Skalweit; Michael E Harris; Louis B Rice; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance.

Authors:  Stilianos Katsaragakis; Haridimos Markogiannakis; Konstantinos G Toutouzas; Panagiotis Drimousis; Andreas Larentzakis; Eleni-Maria Theodoraki; Dimitrios Theodorou
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

8.  Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam.

Authors:  Anna S Levin; Carlos E Levy; A Edison I Manrique; Eduardo A S Medeiros; Silvia F Costa
Journal:  Int J Antimicrob Agents       Date:  2003-01       Impact factor: 5.283

9.  The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace.

Authors:  Ignasi Roca; Paula Espinal; Xavier Vila-Farrés; Jordi Vila
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

10.  Carbapenem-resistant Acinetobacter baumannii from Brazil: role of carO alleles expression and blaOXA-23 gene.

Authors:  Erica Lourenço Fonseca; Erica Scheidegger; Fernanda S Freitas; Rosângela Cipriano; Ana Carolina P Vicente
Journal:  BMC Microbiol       Date:  2013-11-06       Impact factor: 3.605

View more
  27 in total

1.  Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.

Authors:  Richard A Preston; Grigor Mamikonyan; Stephane DeGraff; James Chiou; Christopher J Kemper; Allan Xu; Mushtaque Mastim; Ravindra Yeole; Rajesh Chavan; Anasuya Patel; H David Friedland; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model.

Authors:  S S Bhagwat; H Periasamy; S S Takalkar; S R Palwe; H N Khande; M V Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 3.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

4.  Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Anasuya Patel; Rajesh Chavan; Ravindra Yeole; H David Friedland; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 5.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Burcu Isler; Yohei Doi; Robert A Bonomo; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

6.  WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

7.  In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.

Authors:  Bartolome Moya; Isabel M Barcelo; Gabriel Cabot; Gabriel Torrens; Snehal Palwe; Prashant Joshi; Kushal Umarkar; Swapna Takalkar; Hariharan Periasamy; Sachin Bhagwat; Mahesh Patel; German Bou; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 8.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

Review 9.  The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.

Authors:  Krisztina M Papp-Wallace
Journal:  Expert Opin Pharmacother       Date:  2019-09-09       Impact factor: 3.889

Review 10.  What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  Henrietta Abodakpi; Audrey Wanger; Vincent H Tam
Journal:  Clin Lab Med       Date:  2019-07-06       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.